Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GranaGard
- Development stage
- Unknown
- Lead developer
- Granalix
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
GranaGard is a neuroprotective nutraceutical formulation containing a high concentration of punicic acid (Omega-5), a polyunsaturated fatty acid derived from pomegranate seed oil. Developed by Granalix BioTechnologies, the product utilizes a patented self-emulsifying drug delivery system (SEDDS) to create a nano-emulsion that enhances the bioavailability of punicic acid and facilitates its passage across the blood-brain barrier. Once in the brain, punicic acid is converted into conjugated linoleic acid (CLA), which exerts potent antioxidant effects by scavenging reactive oxygen species and inhibiting lipid peroxidation in neuronal membranes. This mechanism is intended to mitigate the oxidative stress associated with neurodegenerative conditions such as Alzheimer's disease, Multiple Sclerosis, and Creutzfeldt-Jakob Disease. GranaGard is currently marketed as a dietary supplement for cognitive health and has been evaluated in clinical trials for its potential to slow symptomatic progression in neurodegenerative disorders.
- Brand names
- GranaGard
- Other names
- pomegranate seed oil nano-emulsionpunicic acid nano-emulsion
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on GranaGard.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GranaGard.